Rhythm Pharmaceuticals (RYTM) Long-Term Investments (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Long-Term Investments data on file, last reported at $2.5 million in Q1 2026.

• On a quarterly basis, Long-Term Investments fell 64.75% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $2.5 million, a 64.75% decrease from a year earlier, with the FY2025 full-year figure at $3.3 million, down 55.15% from the prior year.
• Long-Term Investments for Q1 2026 stood at $2.5 million, down from $3.3 million in the prior quarter.
• Over the last five years, Long-Term Investments for RYTM reached as high as $18.4 million in Q1 2022 and fell as low as $2.2 million in Q2 2025.
• Historically, Long-Term Investments has averaged $11.3 million across 5 years, with a median of $13.8 million in 2024.
• Across the five-year window, Long-Term Investments surged 48.26% in 2022 and plunged 82.59% in 2025, its largest moves.
• Year by year, Long-Term Investments stood at $16.7 million in 2022, then dropped by 9.94% to $15.0 million in 2023, then sank by 51.16% to $7.3 million in 2024, then slumped by 55.15% to $3.3 million in 2025, then slipped by 23.37% to $2.5 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $2.5 million in Q1 2026, $3.3 million in Q4 2025, and $2.5 million in Q3 2025.